OLEMA ONCOLOGY, INC.

CHARTER OF THE SCIENCE AND TECHNOLOGY COMMITTEE OF THE BOARD OF DIRECTORS

PURPOSE

The purpose of the Science and Technology Committee (the "***Committee***") of the Board of Directors of Olema Oncology, Inc. (the "***Company***") is to help the Board oversee the Company's research and clinical development functions and activities ("***R&D***") to support the goals of the Company.

COMPOSITION

The members of the Committee, including the Chairperson, will be members of the Board appointed by, and will serve at the discretion of, the Board. The number of individuals serving on the Committee shall be fixed by the Board from time to time and the Board shall designate one member of the Committee to serve as the Chairperson of the Committee (the "***Chairperson***"). Vacancies occurring on the Committee will be filled by the Board. Resignation or removal of a Committee member from the Board for any reason will automatically constitute resignation or removal from the Committee.

AUTHORITY

The Committee shall have the resources and authority appropriate to discharge its responsibilities, including the authority to obtain advice and assistance from consultants to advise the Committee and have free access to members of management. The Company shall provide for appropriate funding, as determined by the Committee, for payment of compensation to any consultants retained by the Committee.

The Committee also may form and delegate authority to one or more subcommittees consisting of one or more members of the Board (whether or not he, she or they are on the Committee) to the extent allowed under applicable law and stock exchange listing requirements. By delegating an issue to the Chairperson or a subcommittee, the Committee does not surrender any authority over that issue. Any action or decision of the Chairperson or a subcommittee will be presented to the full Committee at its next scheduled meeting.

RESPONSIBILITIES

The Committee's responsibilities are for oversight, as described under "Purpose" above. The members of the Committee are not employees of the Company, and they do not perform management's functions. The Committee relies on the expertise and knowledge of management in carrying out its oversight responsibilities. The Committee shall have the following responsibilities, provided, however, that this list of responsibilities is intended to be a guide and to remain flexible to account for changing circumstances and needs. Accordingly, the Committee may depart from or supplement such responsibilities, and establish policies and procedures, to the extent permitted by applicable law and stock exchange listing requirements. The Board will retain the right to act on all such matters without limiting the Committee's authority, subject to compliance with applicable law and stock exchange listing requirements.

1. Scientific Review. In furtherance of its oversight responsibilities, the Committee will periodically review and advise on the following:

(a) the overall scientific, clinical, and regulatory strategies underlying the Company's R&D efforts;

(b) the Company's allocation of resources to and prioritization of each of its major clinical programs and earlier-stage research programs;

(c) the capability and skill set of the Company's research and development related functions;

(d) significant emerging trends and issues in the Company's disease areas of focus; and

(e) such other functions are requested by the Board from time to time.

2. Reporting to the Board. The Committee will report and make recommendations to the Board with regard to the Company's R&D organization and programs as it deems appropriate or when requested by the Board.

3. Committee Self-Assessment. The Committee will evaluate its performance and the adequacy of this Charter periodically as the Committee deems appropriate, or as frequently as may be required by the SEC and stock exchange listing standards.

MEETINGS AND MINUTES

The Committee will meet whenever its members deem a meeting necessary or appropriate. The Committee will determine where and when to meet. The Committee may exclude from its meetings any persons it deems appropriate in order to carry out its responsibilities. Unless otherwise determined by the Committee, each regularly scheduled meeting will conclude with an executive session that excludes members of management.

The Committee will maintain written minutes of its meeting and regularly report to the Board on its actions and recommendations. The Committee may act by unanimous written consent; when it does so, those actions will be filed in the minute book.

Approved by the Board of Directors: October 15, 2026
Effective: November 12, 2026